TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nail growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidents of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of JNJ-42165279 as measured by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of JNJ-42165279 as measured by AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway pathology endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Target Validation endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematic fructosamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Persistent Anogenital Infection With HPV
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of HGAIN Associated With HPV
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Penile/Scrotal Condyloma
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of atypical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain induced by patch QUTENZA®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in degree of itching rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital discharge - alive
Endpoint domain: Mortality/survival
Primary endpoint: Bone Mineral Density of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Tinnitus Loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of failure with sonographic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Visual Analogue Scale (VAS) for pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) rates at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of universal familial hypercholesterolemia screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric mean titer to hepatitis B surface antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in interpersonal difficulties
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improved management of feelings and moods
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in problem behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion Adherent to ARV and Psychotropic Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSV-attributable GP consultation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RSV-attributable hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RSV-attributable death
Endpoint domain: Mortality/survival
Primary endpoint: Fibrin clot properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg Blood Flow Response to Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-stimulated Leg Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with clinically relevant findings in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of global tolerability by the investigator on a 4-point rating scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and severity of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postpartum Readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of catheter-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Harmful to Beneficial Bacterial Genera in Fecal Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: In-stent late luminal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of 3D-RWC-TVS and CTC in diagnosing rectosigmoid endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in SELENA-SLEDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in luteinizing hormone pulse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: General Self-Sufficiency Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Well-being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: number of acute episodes of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in The Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle brachial pressure index (ABPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Posterior Tibial Artery Diameter (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pituitary gonadotropin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of congenital hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean pharmacokinetic parameters (Cmax, Cmin, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Anxiety Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alcohol Use, Quantity and Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinking to Cope
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sweets consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory control in response to high-sugar foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Concentrations of TFV-DP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severity Score of Protective Qi Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of PQD Status as Assessed by Traditional Methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean days of postoperative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reproducibility of non-invasive pressure-volume analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between invasive and non-invasive pressure-volume analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cecal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonoscope Withdrawal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects with symptomatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Color Vision Discrimination 1 Hour Post Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Visual Acuity 1 Hour Post Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Pupil Dilation 1 Hour Post Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure 1 Hour Post Dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in Study Eye Severity of Diabetic Retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Overall User Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and severity of treatment emergent ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Injection Site Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in Clinical Attachment Level of Periodontal Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Tumour Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Participant Symptoms of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days Spent on Supplemental Oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma hydromorphone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood vitamin and mineral concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk factors in EoE diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of meropenem above 8 mg/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS) after 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Probability of occurrence of a significant adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf Motor Function Test (WMFT)-Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wolf Motor Function Test (WMFT)-Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast and total inflammatory cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in quantity of microbial DNA extracted from stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in microbial burden of stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Achievement of hemoglobin equal or above 11 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With at Least One Hemoglobin Cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the concentration-time curve from 0 to the last quantifiable concentration (AUC0-tlast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from 0 to infinity (AUC0 ∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to general anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Resolution of Actinic Keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sleep Efficiency index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Restless Legs Syndrome (RLS) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Suicide Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability and Initiation of Mental Health Care and Substance Use Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Suicide-related Coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Intolerance Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS scores for headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity using ICG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 11C-acetate Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net zinc balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum worst pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostaglandin E2 (PGE2) levels within Aberrant Crypt Foci (ACF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time and estimation of treatment retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinesia Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uptake and washout of {I123}MNI-168
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Investigator Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of re-bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EuroQuol-5D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intra- und perioperative implant-related Adverse Events (AE) and complications until discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative AE up to 10 years after the surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Survival, Kaplan Meier
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cephalic sensory dermatomal spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-weighted Summed Pain Intensity Difference (SPID) Over the 1-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Glenoid Component Placement (Inclination and Version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in Glenoid Component Placement (AP and SP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pattern Electroretinogram Amplitude (PERG P50-N95 A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional outcome measured with the DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease activity specific score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of narcotizing enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean maximum IMT slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Tolerability Assessed by Adverse Event and Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in HbA1c at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healing rate after esophageal fistula repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child development composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Children's behavior and composite score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean intraoperative PCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean postoperative PCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient satisfaction with mammography experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adenoma and polyp Detection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cholesterol absorption efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in asthma quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of falling
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of CD19/CD22 CAR T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful manufacture and expansion of CAR T cells
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in psoriasis measured by PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema, scaling, and thickness of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Behavior Problems on the Child Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Total Behavior Problems on the Youth Self Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Irritability & Agitation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of subretinal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation coefficient of Ktrans and ADC with microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks Posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for the diagnosis of advanced hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Circulating levels of EG-VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Nottingham Health Profile, First section (NHP-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life scale (QoLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in concentration of eosinophils in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Seroconversion of HTNV and PUUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Candida infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: WOMAC Index of Osteoarthritis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Macular Hole Closure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contractility index of the right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disappearance of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of CMX001 oral suspension
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma pharmacokinetics of CMX001 and cidofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological response at Test of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0~t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0~inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Kupperman Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerance dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes